Study Shows Colchicine Use in Patients with Gout May Reduce Cardiovascular Event Rates

It is well known that cardiovascular event rates are higher in patients with various inflammatory conditions. A recent study by Dr. Daniel Solomon and colleagues at Harvard revealed an apparent link between large reductions in cardiovascular events in 501 patients with gout who used colchicine over a 16.5 month period vs. 501 similar patients with gout who did not use colchicine. Investigators looked at a composite of stroke, myocardial infarction, and transient ischemic attack as the primary outcome. All-cause mortality, revascularization procedures, and primary cardiovascular events made up secondary outcomes. Adjustments to the data included such covariates as: race, gender, age, diabetes, hypertension, chronic kidney disease, smoking, body mass index, and the use of aspirin, NSAIDS or selective COX-2 inhibitors, statins, antihypertensives, allopurinol, and oral steroids. In gouty subjects taking the colchicine, there was a stunning 49% reduction in cardiovascular events and a 73% lower all-cause mortality rate. Dr. Solomon and authors were clear to state that the trial is “hypothesis generating” but also mentioned that it may be worthwhile having a discussion with patients who have gout to assess whether the patient might tolerate colchicine 0.6 mg/day as “additional preventive therapy”, providing there are no contraindications of course.  See a study published online

Share this: